Januvia litigation
Claims allege that the diabetes drug Januvia was linked to pancreatitis and pancreatic cancer risks that were not adequately disclosed.
Free case review
What the claims allege
Januvia (sitagliptin) belongs to the incretin class of diabetes drugs. Researchers and adverse event databases raised questions about pancreatic inflammation and precancerous changes, and claims allege those risks deserved stronger warnings than the label provided.
Injuries named in the litigation
- Acute pancreatitis
- Pancreatic cancer
Who may qualify
If you used Januvia or Janumet and were hospitalized with pancreatitis or diagnosed with pancreatic cancer, you may have a claim. The review is free and confidential, and we will give you an honest answer either way. You pay attorney's fees only if we recover for you.
Call (888) 391‑1315 or use the form for a free, confidential review. You pay attorney's fees only if we recover for you.